Compare Stocks: MCRB, NKTX, MDWD, and MOLN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MCRB Seres Therapeutics	$4.56	$5.77	$4.32 ▼ $29.98	$45.83M	0.2	64,740 shs	45,314 shs
MDWD MediWound	$13.21	$14.28	$13.06 ▼ $20.30	$169.75M	0.15	61,302 shs	79,831 shs
MOLN Molecular Partners	$4.40	$4.02	$3.53 ▼ $5.36	$177.67M	1.08	931 shs	505 shs
NKTX Nkarta	$2.66	$2.63	$1.70 ▼ $3.72	$190.51M	0.93	613,975 shs	1.11 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MCRB Seres Therapeutics	0.00%	+0.44%	-8.25%	-42.42%	-76.54%
MDWD MediWound	0.00%	-2.58%	-7.17%	-20.33%	-24.94%
MOLN Molecular Partners	0.00%	+7.19%	+11.96%	+9.59%	+17.02%
NKTX Nkarta	0.00%	+14.16%	+17.18%	-12.21%	+12.24%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MCRB Seres Therapeutics	$4.56	$5.77	$4.32 ▼ $29.98	$45.83M	0.2	64,740 shs	45,314 shs
MDWD MediWound	$13.21	$14.28	$13.06 ▼ $20.30	$169.75M	0.15	61,302 shs	79,831 shs
MOLN Molecular Partners	$4.40	$4.02	$3.53 ▼ $5.36	$177.67M	1.08	931 shs	505 shs
NKTX Nkarta	$2.66	$2.63	$1.70 ▼ $3.72	$190.51M	0.93	613,975 shs	1.11 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MCRB Seres Therapeutics	0.00%	+0.44%	-8.25%	-42.42%	-76.54%
MDWD MediWound	0.00%	-2.58%	-7.17%	-20.33%	-24.94%
MOLN Molecular Partners	0.00%	+7.19%	+11.96%	+9.59%	+17.02%
NKTX Nkarta	0.00%	+14.16%	+17.18%	-12.21%	+12.24%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MCRB Seres Therapeutics	2.25	Hold	$17.00	272.81% Upside
MDWD MediWound	2.25	Hold	$33.00	149.81% Upside
MOLN Molecular Partners	2.25	Hold	$8.38	90.34% Upside
NKTX Nkarta	2.86	Moderate Buy	$11.20	321.05% Upside

Current Analyst Ratings Breakdown

Latest MCRB, NKTX, MDWD, and MOLN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$32.00 ➝ $30.00
8/14/2026	NKTX Nkarta	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$11.00 ➝ $10.00
8/11/2026	MCRB Seres Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	NKTX Nkarta	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$14.00
7/17/2026	MDWD MediWound	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/8/2026	MOLN Molecular Partners	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/6/2026	MOLN Molecular Partners	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/24/2026	NKTX Nkarta	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/23/2026	MCRB Seres Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/23/2026	MCRB Seres Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
6/23/2026	MCRB Seres Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 8/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MCRB Seres Therapeutics	$790K	58.01	$1.09 per share	4.20	$4.89 per share	0.93
MDWD MediWound	$16.96M	10.01	N/A	N/A	$3.40 per share	3.89
MOLN Molecular Partners	$5.65M	31.45	N/A	N/A	$2.40 per share	1.83
NKTX Nkarta	N/A	N/A	N/A	N/A	$4.40 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MCRB Seres Therapeutics	$5.70M	-$2.43	N/A	N/A	N/A	-1,192.94%	-114.82%	-34.15%	11/4/2026 (Estimated)
MDWD MediWound	-$23.88M	-$1.80	N/A	N/A	N/A	-170.10%	-47.24%	-24.27%	N/A
MOLN Molecular Partners	-$74.41M	-$1.94	N/A	N/A	N/A	N/A	-66.62%	-54.85%	8/25/2026 (Estimated)
NKTX Nkarta	-$104.08M	-$1.57	N/A	N/A	N/A	N/A	-39.64%	-30.45%	11/10/2026 (Estimated)

Latest MCRB, NKTX, MDWD, and MOLN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/25/2026	Q2 2026	MOLN Molecular Partners	-$0.45	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	MDWD MediWound	-$0.7617	-$0.77	-$0.0083	-$0.77	$2.59 million	$3.09 million
8/10/2026	Q2 2026	NKTX Nkarta	-$0.3603	-$0.54	-$0.1797	-$0.54	N/A	N/A
8/5/2026	Q2 2026	MCRB Seres Therapeutics	-$2.18	$0.47	+$2.65	$0.47	$0.18 million	$0.74 million
5/27/2026	Q1 2026	MDWD MediWound	-$0.65	-$0.23	+$0.42	-$0.23	$3.37 million	$1.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MCRB Seres Therapeutics	N/A	2.11	2.11
MDWD MediWound	N/A	2.32	2.09
MOLN Molecular Partners	N/A	9.43	9.43
NKTX Nkarta	N/A	7.98	7.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MCRB Seres Therapeutics	59.34%
MDWD MediWound	46.83%
MOLN Molecular Partners	26.55%
NKTX Nkarta	80.54%

Insider Ownership

Company	Insider Ownership
MCRB Seres Therapeutics	5.20%
MDWD MediWound	9.20%
MOLN Molecular Partners	5.93%
NKTX Nkarta	9.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MCRB Seres Therapeutics	330	10.05 million	9.52 million	Optionable
MDWD MediWound	80	12.85 million	11.67 million	Optionable
MOLN Molecular Partners	180	40.38 million	37.98 million	Not Optionable
NKTX Nkarta	140	71.62 million	64.61 million	Optionable

MCRB, NKTX, MDWD, and MOLN Headlines

Recent News About These Companies

Monaco Asset Management SAM Makes New Investment in Nkarta, Inc. $NKTX

August 17, 2026 | marketbeat.com

Stifel Nicolaus Cuts Nkarta (NASDAQ:NKTX) Price Target to $10.00

August 17, 2026 | americanbankingnews.com

Nkarta (NASDAQ:NKTX) Downgraded to Strong Sell Rating by Wall Street Zen

August 15, 2026 | americanbankingnews.com

Nkarta (NASDAQ:NKTX) Stock Rating Lowered by Wall Street Zen

August 15, 2026 | marketbeat.com

HC Wainwright Analysts Reduce Earnings Estimates for Nkarta

August 15, 2026 | americanbankingnews.com

Stifel Nicolaus Has Lowered Expectations for Nkarta (NASDAQ:NKTX) Stock Price

August 14, 2026 | marketbeat.com

Equities Analysts Set Expectations for Nkarta Q3 Earnings

August 13, 2026 | marketbeat.com

Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights

August 10, 2026 | markets.businessinsider.com

Nkarta (NASDAQ:NKTX) Posts Quarterly Earnings Results, Misses Estimates By $0.18 EPS

August 10, 2026 | marketbeat.com

Nkarta Reports Continued Enrollment in Ntrust Autoimmune Trials and $243.2 Million Cash Position, Reaffirms Runway Into 2029

August 10, 2026 | quiverquant.comQ

Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Moderate Buy" by Analysts

August 9, 2026 | marketbeat.com

Nkarta (NKTX) Stock Forecast & Price Target

August 7, 2026 | investing.com

Nkarta (NKTX) Projected to Post Quarterly Earnings on Tuesday

August 4, 2026 | marketbeat.com

Nkarta (NASDAQ:NKTX) Upgraded at Wall Street Zen

August 2, 2026 | marketbeat.com

Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development

July 23, 2026 | globenewswire.com

Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

June 26, 2026 | globenewswire.com

Nkarta Shareholders Back Directors, Auditor and Annual Say-on-Pay

June 11, 2026 | tipranks.com

Nkarta Inc Ordinary Shares NKTX

May 16, 2026 | morningstar.comM

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

May 14, 2026 | finance.yahoo.com

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

May 12, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), QT Imaging Holdings (QTI) and Cardiff Oncology (CRDF)

April 23, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB, NKTX, MDWD, and MOLN Company Descriptions

Seres Therapeutics NASDAQ:MCRB

$4.56 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

MediWound NASDAQ:MDWD

$13.21 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Molecular Partners NASDAQ:MOLN

$4.40 0.00 (0.00%)

As of 08/21/2026 12:43 PM Eastern

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Nkarta NASDAQ:NKTX

$2.66 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MCRB, NKTX, MDWD, and MOLN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MCRB, NKTX, MDWD, and MOLN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MCRB, NKTX, MDWD, and MOLN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB, NKTX, MDWD, and MOLN Company Descriptions

Seres Therapeutics NASDAQ:MCRB

MediWound NASDAQ:MDWD

Molecular Partners NASDAQ:MOLN

Nkarta NASDAQ:NKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MCRB, NKTX, MDWD, and MOLN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MCRB, NKTX, MDWD, and MOLN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MCRB, NKTX, MDWD, and MOLN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB, NKTX, MDWD, and MOLN Company Descriptions

Seres Therapeutics NASDAQ:MCRB

MediWound NASDAQ:MDWD

Molecular Partners NASDAQ:MOLN

Nkarta NASDAQ:NKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools